Research programme: small molecule pharmacological chaperones - ATLAS Molecular Pharma
Alternative Names: Pharmacological chaperones - ATLAS Molecular PharmaLatest Information Update: 09 Feb 2022
At a glance
- Originator Atlas Molecular Pharma
- Class Small molecules
- Mechanism of Action FAHD1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Creutzfeldt-Jakob disease; Erythropoietic porphyria; Tyrosinaemia type I
Most Recent Events
- 17 Jan 2022 Small molecule chaperones - ATLAS Molecular Pharma/CIC Biogune is available for licensing as of 17 Jan 2022. https://atlasmolecularpharma.com/about/
- 17 Jan 2022 ATLAS Molecular Pharma plans preclinical studies in Liver disorders
- 12 Nov 2021 Early research in Creutzfeldt-Jakob disease in Spain (unspecified route) (ATLAS Molecular Pharma pipeline, January 2022)